PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP

NCT02566603 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

15

Enrollment

INDUSTRY

Sponsor class

Stopped Enough data has been collected to allow analysis of the safety profile and risk-benefit.

Conditions

Immune Thrombocytopenia

Interventions

DRUG: PRTX-100
DRUG: PRTX-100
DRUG: PRTX-100
DRUG: PRTX-100
DRUG: PRTX-100

Sponsor

Protalex, Inc.